Danish biopharma Forward Pharma (Nasdaq: FWP) says it is considering its options after the US Court of Appeals for the Federal Circuit denied the company rights to royalties relating to the blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate).
The court upheld the March 2017 decision of the Patent Trial and Appeal Board, which had found that the patents held by US biotech major Biogen (Nasdaq: BIIB) on Tecfidera were valid.
In case the ruling had gone the other way, Biogen had agreed to pay Forward $1.25 billion in January 2017 to license the company’s patents covering its multiple sclerosis drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze